Jun Hee-Sook
Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Korea.
Korean Diabetes J. 2010 Apr;34(2):77-83. doi: 10.4093/kdj.2010.34.2.77. Epub 2010 Apr 30.
Reduction of beta cell function and a beta cell mass is observed in both type 1 and type 2 diabetes. Therefore, restoration of this deficiency might be a therapeutic option for treatment of diabetes. Islet transplantation has benefits, such as reduced incidence of hypoglycemia and achievement of insulin independence. However, the major drawback is an insufficient supply of islet donors. Transplantation of cells differentiated in vitro or in vivo regeneration of insulin-producing cells are possible approaches for beta cell/islet regenerative therapy. Embryonic and adult stem cells, pancreatic ductal progenitor cells, acinar cells, and other endocrine cells have been shown to differentiate into pancreatic beta cells. Formation of fully functional beta cells and the safety of these cells are critical issues for successful clinical application.
在1型和2型糖尿病中均观察到β细胞功能和β细胞数量的减少。因此，恢复这种缺陷可能是糖尿病治疗的一种选择。胰岛移植有诸多益处，如低血糖发生率降低以及实现胰岛素非依赖。然而，主要缺点是胰岛供体供应不足。体外分化细胞的移植或体内胰岛素产生细胞的再生是β细胞/胰岛再生治疗的可行方法。胚胎干细胞、成体干细胞、胰腺导管祖细胞、腺泡细胞和其他内分泌细胞已被证明可分化为胰腺β细胞。形成功能完全的β细胞以及这些细胞的安全性是成功临床应用的关键问题。
